CorriXR Therapeutics was voted “Most Promising New Company” by attendees last week at the first-ever Delaware BioScience Association (Delaware Bio) conference.
The first spin-out of ChristianaCare’s Gene Editing Institute, CorriXR is a cancer-focused biotherapeutics development company with a gene editing platform technology.
“It was an honor to present CorriXR Therapeutics and win Most Promising New Company at Delaware’s DNA 2023 Life Science Conference,” said Dr. Eric Kmiec, company founder, and CEO. “We thank Delaware Bio for providing this opportunity to strengthen relationships and connections in the life sciences ecosystem in the state. We are grateful for the continued support as a start-up company developing novel gene editing therapies for cancer.”
Runners up for the top prize were Cosmos Pharmaceuticals, a medical device company focused on the relationship between medication adherence and patient outcomes, and Hartlon, a start-up developing a resorbable vascular stent designed to salvage limbs that are at risk of amputation by restoring blood flow below the knee.
Each of the seven companies selected to participate made three-minute pitches to the conference audience. All attendees were eligible to vote through the conference app. As the top vote-getter, CorriXR will receive a $2,500 prize and Cosmos and Hartlon each will receive $1,000.
“It was a privilege to present my start-up, Cosmos Pharmaceuticals, at Delaware Bio’s first conference. The presentation, feedback, and most importantly the attendees that I connected with made this event special,” said Cosmos founder Alexander Colton. “Delaware’s tightly connected entrepreneurial hub is a critical part of Cosmos’s success and we are excited to launch our product FortisKap later this year from my home state.”
“I greatly appreciated the opportunity to interact with leaders in the Delaware life science ecosystem,” said Jack Scanlon of Hartlon. “We are so pleased by this recognition – it makes clear that people understand both the severity of the health problem Hartlon is addressing and the transformational potential of our breakthrough drug delivery technology.”
Held on May 11, Delaware’s DNA: 2023 Life Science Conference convened a collection of global, regional and state bioscience sector leaders for a full-day program exploring the industry’s most critical issues and opportunities. Event speakers included Gov. John Carney, CEOs, federal government officials, and top industry investors from JP Morgan, Bernstein and Aisling Capital along with scientific presentations by Delaware researchers.
“We congratulate CorriXR, Cosmos and Hartlon on this exciting achievement and recognition, and thank all our participating companies for helping make our first-ever conference a huge success,” said Michael Fleming, president of Delaware Bio. “Small life science companies are the largest, and fastest-growing segment of our membership and the pitch competition demonstrated the strength and diversity of our startup ecosystem.”
Other firms participating in the pitch event were:
BioCurie – BioCurie is developing an AI software platform that will revolutionize cell and gene therapy (CGT) production to make these lifesaving therapies faster, better, and cheaper.
Cellergy Pharma – Cellergy Pharma develops novel immunotherapies for treating severe allergic diseases.
Innovative Precision Health – Innovative Precision Health (IPH) is a healthcare technology company that provides comprehensive solutions for precision health. Our platform integrates data collection, analysis, and interpretation and is implemented and validated nationwide.
Nitro Biosciences – Nitro Biosciences is a startup company from the University of Delaware developing a live bacterial vaccine platform to target diseases/antigens normally hidden from the immune system.
